Pharmaceutical - Pharmaceutical, Merck & Co

Filter

Current filters:

PharmaceuticalMerck & Co

Popular Filters

1 to 25 of 261 results

Belsomra could become first-line insomnia therapy, says GlobalData

Belsomra could become first-line insomnia therapy, says GlobalData

18-08-2014

Insomnia treatment Belsomra (suvorexant) from US pharma giant Merck & Co has the potential to become…

BelsomraChemistryCyclopyrrolonesInsomniaMarkets & MarketingMerck & CoNeurologicalOrganic chemistryPharmaceuticalUSA

Merck’s Belsomra gets FDA approval for insomnia

Merck’s Belsomra gets FDA approval for insomnia

14-08-2014

Pharma giant Merck & Co has received US Food and Drug Administration approval for its insomnia treatment…

BelsomraMerck & CoNeurologicalPharmaceuticalRegulationSedativesUSA

Lilly and Boehringer closing in on diabetes market lead with Jardiance approval

Lilly and Boehringer closing in on diabetes market lead with Jardiance approval

07-08-2014

With the recent approval of Jardiance (empagliflozin) in the USA, Eli Lilly and its partner, German family-owned…

Boehringer IngelheimDiabetesEli LillyEli Lilly and CompanyJanuviaJardianceMarkets & MarketingMerck & CoPharmaceuticalTradjenta

Acute coronary syndrome treatment market to more than triple by 2023

Acute coronary syndrome treatment market to more than triple by 2023

30-07-2014

The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary…

Acute coronary syndromealirocumabAmgenBayerCardio-vascularEuropeevolocumabJapanMarkets & MarketingMerck & CoPfizerPharmaceuticalSanofiUSAXareltoZontivity

Merck's revenue drops 1% but still beats analysts' estimates for 2nd-qtr

Merck's revenue drops 1% but still beats analysts' estimates for 2nd-qtr

29-07-2014

Global revenue at pharma giant Merck & Co slipped 1% but the company has still exceeded analysts’ estimates…

FinancialFinancial accountingGardasilHepatitis CIsentressMerckMerck & CoNasonexPharma giantPharmaceuticalRemicadeUSAVytorinZetia

Global insulin market set to reach $32.24 billion in 2019

Global insulin market set to reach $32.24 billion in 2019

28-07-2014

The global insulin market was valued at $19.99 billion in 2012 and is expected to expand at a compound…

AfrezzaChinaDiabetesEli LillyGlobalInsulinLY2605541MannKindMarkets & MarketingMerck & CoMK-1293NN1218Novo NordiskPharmaceutical

Merck strengthens commitment to Chinese growth market

Merck strengthens commitment to Chinese growth market

23-07-2014

Germany’s Merck KGaA, a leading company for high-tech products in the pharmaceutical and chemical sectors,…

ChinaFinancialMerckMerck KGaAPharmaceuticalProductionResearch

Jounce appoints Richard Murray from Merck

Jounce appoints Richard Murray from Merck

11-07-2014

US-based oncology specialist Jounce Therapeutics has announced the appointment of Richard Murray to chief…

BoardroomJounce TherapeuticsMerck & Co.OncologyPharmaceuticalRichard Murray

EMA accepts Merck’s pembrolizumab MAA for review

EMA accepts Merck’s pembrolizumab MAA for review

01-07-2014

US pharma giant Merck & Co says that the European Medicines Agency has accepted for review a Marketing…

EuropeMerck & CoOncologypembrolizumabPharmaceuticalRegulation

Positive data on Merck & Co’s nausea drug Emend Ph III trial in children

Positive data on Merck & Co’s nausea drug Emend Ph III trial in children

30-06-2014

Positive results have been announced by US pharma giant Merck & Co from a global, investigational Phase…

EmendMerck & CoOncologyPharmaceuticalRegulationResearch

Merck & Co returns rights to Endocyte’s vintafolide

Merck & Co returns rights to Endocyte’s vintafolide

18-06-2014

Shares of USA-based Endocyte fell 19.7% to $6.20 in after-hours trading yesterday, after the company…

CisplatinEnd point of clinical trialsEndocyteHealth Medical PharmaLicensingMerck & CoOncologyPEGylationPharmaceuticalPlatinum-resistant ovarian cancervintafolide

Drug pricing power led by hepatitis C, diabetes and cancer

Drug pricing power led by hepatitis C, diabetes and cancer

13-06-2014

Hepatitis C, diabetes and cancer are sustaining high pricing power through innovation according to Morningstar's…

AbbVieAntibiotics and Infectious diseasesBiogen IdecCopaxoneDiabetesGenericsGilead SciencesMerck & CoOncologyPharmaceuticalPricingTecfideraTeva Pharmaceutical IndustriesUSA

Decision Resources Group analyst’s view on Merck’s decision to acquire Idenix

Decision Resources Group analyst’s view on Merck’s decision to acquire Idenix

12-06-2014

Given the huge potential, and interest in, the hepatitis treatment market, and US pharma giant Merck…

Anti-viralsIdenix PharmaceuticalsMerck & CoMergers & AcquisitionsPharmaceutical

Excitement as Merck releases new data on cancer drug candidate pembrolizumab

Excitement as Merck releases new data on cancer drug candidate pembrolizumab

03-06-2014

The findings released at the 2014 American Society of Clinical Oncology (ASCO) conference in Chicago…

Merck & CoOncologypembrolizumabPharmaceuticalResearch

Merck and Endocyte pull CMA for vintafolide and companion imaging component in EU

20-05-2014

US pharma giant Merck & Co and Endocyte have withdrawn their conditional marketing authorization applications…

EndocyteEuropeMerck & CoOncologyPharmaceuticalRegulationResearchvintafolide

Merck KGaA takes currency hit in first quarter 2014

Merck KGaA takes currency hit in first quarter 2014

15-05-2014

German pharma and chemicals major Merck KGaA has reported first-quarter 2014 financial result, saying…

Business FinanceChemicalsEURFinancialMerckMerck KGaAPharmaceuticalSerono

Merck & Co sells ophthalmic brands and Colorado biologicals unit

Merck & Co sells ophthalmic brands and Colorado biologicals unit

13-05-2014

US pharma giant Merck & Co has entered into two more divestment transactions, following the recent sell-off…

KBI BiopharmaMerck & CoMergers & AcquisitionsOphthalmicsPharmaceuticalProductionSanten Pharmaceuticals

FDA approves Merck & Co’s new blood thinner Zontivity

FDA approves Merck & Co’s new blood thinner Zontivity

09-05-2014

The US Food and Drug Administration yesterday approved US pharma giant Merck & Co’s Zontivity (vorapaxar)…

Cardio-vascularMerck & CoPharmaceuticalRegulationUSAZontivity

Merck & Co updates on near-term opportunities and strategy

Merck & Co updates on near-term opportunities and strategy

07-05-2014

US pharma giant Merck & Co, which has just sold its consumer health care business to Bayer for $14.2…

Merck & CoPharmaceuticalRegulationResearch

Bayer shells out $14.2 billion for Merck & Co OTC business; firms to collaborate on sGC modulators

Bayer shells out $14.2 billion for Merck & Co OTC business; firms to collaborate on sGC modulators

06-05-2014

Confirming strong rumors over the past week or so, German pharma major Bayer confirmed it has agreed…

AdempasBayerLicensingMerck & CoMergers & AcquisitionsPharmaceuticalResearchRespiratory and Pulmonaryvericiguat

Endocyte plummets on decision to stop vintafolide Ph III trial; posts financials

03-05-2014

US pharma giant Merck & Co and partner Endocyte revealed on Friday that the Data Safety Monitoring Board…

EndocyteFinancialMerck & CoOncologyPharmaceuticalResearchvintafolide

1 to 25 of 261 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top